证券代码：600513 证券简称：联环药业 公告编号：2026-008 江苏联环药业股份有限公司 关于公司获得《药品注册证书》的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下简称"国家药监 局"）核准签发的关于盐酸利多卡因凝胶（以下简称"该药品"）的《药品注册证书》，现将相关情况公 告如下： 本次公司获得盐酸利多卡因凝胶的《药品注册证书》，进一步丰富了公司的产品线，有助于提升公司产 品的市场竞争力。上述《药品注册证书》的取得预计不会对公司近期经营业绩产生重大影响。 四、风险提示 公司高度重视药品研发，并严格控制药品研发、生产、销售各环节的质量安全。由于药品的生产、销售 易受到国内医药行业政策变动、招标采购、市场变化等因素影响，存在不确定性，敬请广大投资者审慎 决策，注意投资风险。 二、药品的其他情况 一、《药品注册证书》的主要内容 盐酸利多卡因凝胶适用于局麻药、经尿道施行检查和治疗需局部麻醉者。截至目前，包括公司在内，国 内共有三家企业取得该药 ...

联环药业公告称，近日收到国家药监局核准签发的盐酸利多卡因凝胶《药品注册证书》，该药品规格为 2%（10g:0.2g），注册分类为化学药品3类，视同通过仿制药质量和疗效一致性评价。截至公告披露 日，该项目累计研发投入约726.73万元，此为公司2026年首个生产批件。2024年全国二级以上医院该药 品销售额约4086.45万元。获证将丰富产品线、提升竞争力，预计近期业绩无重大影响。 ...

Core Viewpoint - The rapid growth of online healthcare in China has led to significant issues in the sale of prescription drugs on e-commerce platforms, posing serious risks to consumer safety due to lax regulations and practices [1][5]. Group 1: Prescription Drug Sales Issues - The process for purchasing prescription drugs online is alarmingly simple, with consumers not required to provide medical history or prescriptions, leading to "instant prescriptions" without proper medical evaluation [1][2][3]. - In a practical test, the time taken from consultation to prescription issuance was as short as 10 seconds, highlighting the lack of meaningful interaction between patients and online doctors [2][3]. - Some platforms allow for prescription issuance at any hour, with no restrictions on the timing of orders, further exacerbating the issue of oversight in prescription practices [5]. Group 2: Regulatory Violations - Online platforms are found to be in violation of regulations by displaying prescription drug packaging and information that should not be publicly accessible before prescription approval [6][8]. - Certain platforms promote prescription drugs for uses that exceed their approved indications, misleading consumers and potentially endangering their health [8][10]. - There are instances of products being marketed under names and packaging that closely resemble approved medications, raising concerns about counterfeit drugs and misleading advertising [10][12]. Group 3: Legal Implications - The sale of drugs with altered names and packaging may violate multiple laws, including those against unfair competition and drug management regulations, potentially leading to severe penalties for the sellers [12][13]. - Third-party platforms are urged to enhance their oversight of drug sales to prevent the distribution of unapproved or counterfeit medications, as failure to do so could result in shared liability for regulatory breaches [12].